Serum Soluble CD14 Is a Potential Prognostic Indicator of Recurrence of Human Breast Invasive Ductal Carcinoma With Her2-Enriched Subtype

PLoS ONE - United States
doi 10.1371/journal.pone.0075366
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Resistance to Trastuzumab in HER2-Positive Mucinous Invasive Ductal Breast Carcinoma

Clinical Breast Cancer
Cancer ResearchOncology
2013English

HER2/neu and Ki-67 Expression Predict Non-Invasive Recurrence Following Breast-Conserving Therapy for Ductal Carcinoma in Situ

British Journal of Cancer
Cancer ResearchOncology
2012English

Clinicopathologic Features of Invasive Metaplastic and Micropapillary Breast Carcinoma: Comparison With Invasive Ductal Carcinoma of Breast

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2018English

Invasive Ductal Carcinoma of the Breast With the “Triple-Negative” Phenotype: Prognostic Implications of EGFR Immunoreactivity

Breast Cancer Research and Treatment
Cancer ResearchOncology
2008English

Immunological Subtypes in Breast Cancer Are Prognostic for Invasive Ductal but Not for Invasive Lobular Breast Carcinoma

British Journal of Cancer
Cancer ResearchOncology
2014English

Prognostic Value of Ductal Carcinoma in Situ Component in Invasive Ductal Carcinoma of the Breast: A Surveillance, Epidemiology, and End Results Database Analysis

Cancer Management and Research
Oncology
2018English

P53 Overexpression Is a Predictor of Local Recurrence After Treatment for Both in Situ and Invasive Ductal Carcinoma of the Breast

Journal of Surgical Research
Surgery
2007English

Pancreatic Metastasis From Invasive Ductal Carcinoma of the Breast

The Korean Journal of Medicine
2017English

A Non-Invasive Approach to Explore the Discriminatory Potential of the Urinary Volatilome of Invasive Ductal Carcinoma of the Breast

RSC Advances
ChemistryChemical Engineering
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy